ARVO/Alcon Keynote Session
Sunday, May 7, 12:00 - 1:15pm
Mary-Claire King, PhD
University of Washington
The ARVO 2017 Opening Keynote speaker is Mary-Claire King, PhD, professor of medical genetics at the University of Washington. King has made numerous seminal contributions to genetics. During her doctoral training she found that humans and chimpanzees share 99% of their genome. She was the first to identify and name BRCA1, an inheritable gene associated with breast cancer. In addition to its breast cancer work, King’s lab is also currently pursuing de novo mutations that may cause schizophrenia and identifying the genetic causes of severe inherited disorders in Middle Eastern families. Kings presentation will be the first ARVO Opening Keynote delivered by a woman.
The 2017 Basic/Clinical Lecture will be presented from a clinical perspective to basic researchers.
Sunday, May 7; 5:15 – 7:15pm
Improving global eye health: Beating the odds for neglected and emerging diseases around the world
Contributing Sections/Groups: AP, CL, CO EY, GEN, GL, IM, LV, MOI
Organizers: Yeni Yucel, Timothy Corson, Shahar Frenkel
Speakers: Tin Aung, Paul Courtright, Brenda L. Gallie, Rubens Belfort Jr., Hugh Taylor, Sheila West
Vision Diseases affecting eye health and vision constitute a global burden. However, successes in prevention, understanding, diagnosis, treatment and partnerships are needed to improve care for a number of neglected and emerging diseases. Presenting perspectives from five continents, this symposium will bring together diverse experts to describe the impact of key eye diseases on human health in networks of connected communities from local to global levels.
Beckman-Argyros Award in Vision Research Lecture
Sunday, May 7, 5:30 – 6:30pm
Jeremy Nathans, MD, PhD
Johns Hopkins University, School of Medicine
For almost thirty years, Jeremy Nathans, MD, PhD has been producing transformative breakthroughs in vision science at Johns Hopkins University, which earned him the prestigious 2016 Beckman-Argyros Award in Vision Research. The Arnold and Mabel Beckman Foundation award will help Nathan's lab further their research using molecular genetic approaches to study the development of mammalian retina and embryo. Read more about Nathan's award-winning research in the latest issue of ARVONews.
Proctor Award and Lecture
Monday, May 8, 5:45 - 6:30pm
Gustavo D. Aguirre, VMD, PhD, FARVO (RC)
University of Pennsylvania
From the Cage to the Bedside-Concepts and Strategies in Retinal Gene Therapy
Dr. Aguirre's unique canine models of retinal degeneration have given us invaluable basic information about their counterpart human diseases. Moreover, this preclinical work has established safety and efficacy for most of the clinical trial work in progress on neurotrophic factors (CNTF) as well as gene therapy (RPE5). His most recent work on XLRP demonstrates that gene therapy can successfully arrest advanced photoreceptor and vision loss, dramatically expanding the therapeutic window to late stages of disease.
Mildred Weisenfeld Award and Lecture
Monday, May 8, 6:45 - 7:30pm
Johanna Seddon, MD, MS, FARVO (CL)Tufts University School of Medicine and Tufts Medical Center
Macular Degeneration Epidemiology: Nature-Nurture, Lifestyle Factors, Genetic Risk and Gene-Environment Interactions
Dr. Seddon is Professor and Founding Director of the Ophthalmic Epidemiology and Genetics Service at Tufts, and has been a Trustee and Vice-President of ARVO. She is a pioneer in ophthalmic epidemiology, particularly the study of nutritional, environmental and genetic risk factors for AMD. Enormous contributions include her studies of lifestyle factors which have influenced clinical practice world-wide. Groundbreaking discoveries of common and rare AMD genetic variants shed light on mechanisms and provided targets for therapies. Her predictive modeling insights have laid the groundwork for personalized medicine.
ARVO/Champalimaud Vision Award Lecture
Tuesday, May 9, 5:45 – 7pm
2016 Awardees Speakers Carol Mason and Carla Shatz
|Carol Mason, PhD
|Carla Shatz, PhD
The work of the four awardees, John Flanagan, Christine Holt, Carol Mason and Carla Shatz, has shone light on the connection between the two fundamental organs responsible for vision — the eye and the brain — and their ground-breaking work has greatly advanced the understanding of the visual system. The Antonio Champalimaud Vision Award winners are selected because they are leaders in contributing to high-impact overall vision research. The 2016 awardees were the subject of a recent ARVONews article.
Cogan Award and Lecture
Wednesday, May 10, 5:45 - 6:30pm
Andrew Huberman, PhD (NA)
Stanford University School of Medicine
Visual Restoration and Function: From Genetics to Virtual Reality
Dr. Huberman has more than 15 years of experience studying the development, function and repair of mammalian visual circuits. He has made fundamental discoveries regarding the mechanisms of binocular circuit development, and pioneered the use of genetic and viral tools for labeling and probing specific retinal cells and their associated brain circuits. He is now also forging new paths in retinal disease research by bringing modern genetic tools to the study of glaucoma and optic nerve repair.
Friedenwald Award and Lecture
Wednesday, May 10, 6:45 - 7:30pm
Paul Kaufman, MD (GL)
University of Wisconsin
Presbyopia and Glaucoma - The Missing Link?
Much like the Jonas Friedman himself, Paul Kaufman has had a long and distinguished career of performing pioneering work in several areas of ophthalmic research. Much of our current understanding of the aqueous humor outflow system in the eye, and the mechanisms of many known and novel drugs, have been the direct result of his work. His extensive and superb work on the pathogenesis and treatment of glaucoma, as well as the mechanisms of accommodation has changed the way we practice medicine and has laid the groundwork for future generations of investigators.
ARVO/Alcon Closing Keynote Session
Thursday, May 11, 1:30 - 3:15pm
Donald Zack, MD, PhD
Johns Hopkins University
What’s next in the investigation of genetics of age-related macular degeneration?
The session features a panel of experts who will focus on the next set of potential investigations to further our understanding of the pathogenesis of age-related macular degeneration (AMD) based upon current knowledge of the genetics of AMD. Presenters will explore lessons from other diseases that have taken that translational step in moving from gene discovery to better understanding of functional aspects; approaches to functionalizing rare variants; and the use of biobanks to iterate from discovery to disease mechanism. The panel will discuss how these approaches may help us move forward from our current knowledge of the genetics of AMD to actionable steps to reduce the burden of blindness from AMD.
|Lessons learned from other diseases
|| Approaches to Functionalizing Rare Genetic Variants
||Using Biobanks to Iterate from Discovery to Disease Mechanism
|Pamela Sklar, MD, PhD
Icahn School of Medicine at Mount Sinai
|Terri Manolio, MD, PhD
National Human Genome Research Institute/National Institutes of Health
|Nancy J. Cox, PhD